Research programme: cancer vaccines - Vedantra Pharmaceuticals/Neon Therapeutics

Drug Profile

Research programme: cancer vaccines - Vedantra Pharmaceuticals/Neon Therapeutics

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neon Therapeutics; Vedantra Precision Immunity
  • Class Antigens; Antineoplastics; Cancer vaccines; Immunoconjugates; Peptide vaccines
  • Mechanism of Action CD8 positive T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 31 Oct 2017 Vedantra Pharmaceuticals and Neon Therapeutics extend collaboration for development of neo-antigen cancer vaccines
  • 23 Mar 2017 Cancer vaccines - Vedantra Pharmaceuticals/Neon Therapeutics is available for licensing as of 23 Mar 2017. http://vedantra.com/partnerships
  • 14 Mar 2017 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top